Mitchell Efros

In modern clinical research, competition for eligible subjects is intense, protocols are increasingly complex, and timelines are tighter than ever. Across therapeutic areas, one persistent and costly threat continues to undermine trial integrity: duplicate and professional research subjects. These are individuals who enroll in multiple studies either at the same time or in rapid succession—often …

Read more

Preventing professional patients in clinical trials, duplicate research subjects, and dual enrollment in clinical trials isn’t just a Day 1 problem — it’s a long‑term necessity. In clinical research, subject risk is often assumed to be limited to eligibility at screening. But what happens after randomization? What about long-term follow-up, crossover phases, or open-label extensions? …

Read more

In the world of clinical trials, research sites occasionally have a strange feeling of déjà vu—”It’s you again?” That familiar face showing up for another screening visit may not just be coincidence. In fact, it’s often a warning sign of a growing issue in clinical research: professional patients and duplicate subjects in clinical research. These …

Read more

Studies in clinical research show that duplicate or professional trial participants—individuals enrolling in multiple studies simultaneously—are far more common than many sponsors realize. Rates as high as 10% have been reported in therapeutic areas beyond psychiatry, including dermatology, ophthalmology, respiratory, and others. Each duplicate research subject can skew efficacy, safety, and overall trial integrity. The data: …

Read more

Clinical trials are complex, high-stakes endeavors where every detail matters — yet one hidden risk continues to undermine studies across all therapeutic areas: duplicate and professional research subjects. You may believe your internal checks, EDC reviews, or sponsor-specific solutions have you covered. The reality?Most systems only detect duplicate subjects after they’ve already dosed — or …

Read more

When a clinical trial misses its primary endpoint, the root cause is rarely just the science — more often, it’s hidden threats to the data itself. One of the most overlooked risks is the presence of duplicate research subjects or professional research subjects who enroll in multiple studies or across multiple sites, undermining results and …

Read more

Verified Clinical Trials (VCT) is proud to announce our participation at the upcoming American Diabetes Association (ADA) annual meeting. As clinical research in diabetes, obesity, and GLP-1 therapies continues to expand at a record pace, VCT remains committed to delivering innovative solutions that safeguard data integrity, improve participant safety, and optimize trial outcomes by preventing …

Read more

The race to develop and commercialize GLP-1-based therapies for obesity and diabetes has created unprecedented momentum in clinical research. Dozens of sponsors and CROs are simultaneously conducting trials—often in overlapping geographic regions—with many vying for access to the same pool of patients. While this represents exciting progress in metabolic disease treatment, it also presents a …

Read more

https://healthtechcurated.com/regulatory-and-compliance/how-does-vct-protect-clinical-trials-from-duplicate-subjects/ In the complex realm of clinical trials, preventing the enrollment of duplicate and professional research subjects is critical for maintaining data integrity and ensuring participant safety. As trials expand with overlapping indications and global participation, the risk of unethical subject enrollment increases. These duplicate reseaerch subjects, who join multiple studies without observing necessary washout …

Read more

Detecting and preventing protocol violations before they ever happen. In today’s complex clinical trial landscape, one issue continues to fly under the radar—duplicate research subjects and professional research subjects. These individuals enroll in multiple trials simultaneously or too close together, often crossing therapeutic areas, sponsors, and trial phases. Left unchecked, these subjects introduce significant risk …

Read more